Chardan Capital Initiates Coverage On Century Therapeutics With Buy Rating, Announces Price Target of $19
Chardan Capital Initiates Coverage On Century Therapeutics With Buy Rating, Announces Price Target of $19
查丹資本開始覆蓋世紀治療的買入評級，宣布價格目標為 19 美元
Chardan Capital analyst Geulah Livshits initiates coverage on Century Therapeutics (NASDAQ:IPSC) with a Buy rating and announces Price Target of $19.
查丹資本分析師格拉·利維希茨以買入評級起始對世紀治療（NASDAQ：IPSC）的報導，並宣布目標價為 19 美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。